Virtu Financial LLC Tcr2 Therapeutics Inc. Transaction History

Virtu Financial LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	BUY	$0.83 - $1.44 $15,939 - $27,653	19,204 New	19,204 $19,000
Q1 2022 May 17, 2022	SELL	$2.4 - $4.71 $76,588 - $150,305	-31,912 Closed	0 $0
Q4 2021 Feb 17, 2022	BUY	$4.58 - $8.34 $146,156 - $266,146	31,912 New	31,912 $149,000
Q2 2021 Sep 17, 2021	SELL	$16.41 - $24.71 $268,861 - $404,848	-16,384 Closed	0 $0
Q1 2021 May 19, 2021	BUY	$20.38 - $34.07 $333,905 - $558,202	16,384 New	16,384 $362,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.